Eris Lifesciences Limited
ERIS · Pharma · NSE
₹1,405
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for ERIS yet. Reason: Data Limited.
Updated just now
YieldIQ Score
—
Piotroski F-Score
6/9
Economic Moat
Narrow
Confidence
25%
ROE
15.9%
Debt/Equity
0.60
WACC
9.5%
Market Cap
₹19,463 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
17.7%
Return on capital employed
EV / EBITDA
18.3×
Enterprise multiple
Debt / EBITDA
2.2×
Leverage vs earnings
Interest Coverage
3.1×
EBIT covers interest
Current Ratio
0.89×
Short-term liquidity
Asset Turnover
0.44×
Revenue per ₹ of assets
Revenue CAGR (3Y)
23.3%
3-year revenue growth
Revenue CAGR (5Y)
20.8%
5-year revenue growth
Ratio Trends
ERIS · last 9 annual periods
ROE
15.9%
ROCE
17.7%
Operating Margin
—
Debt / Equity
0.60×
PE
29.0×
EV / EBITDA
18.3×
Historical Financials
ERIS · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹1326 Cr | ₹1662 Cr | ₹1991 Cr | ₹2879 Cr | ₹3115 Cr | +23.8% |
| EBITDA | ₹511 Cr | ₹548 Cr | ₹699 Cr | ₹1036 Cr | ₹1111 Cr | +21.4% |
| EBIT | ₹446 Cr | ₹431 Cr | ₹516 Cr | — | — | +3.7% |
| PAT | ₹406 Cr | ₹382 Cr | ₹392 Cr | ₹352 Cr | ₹620 Cr | +11.1% |
| EPS (diluted) | ₹29.88 | ₹28.07 | ₹28.79 | — | — | -0.9% |
| CFO | ₹378 Cr | ₹292 Cr | ₹486 Cr | ₹1065 Cr | ₹538 Cr | +9.2% |
| CapEx | ₹-121 Cr | ₹-841 Cr | ₹-129 Cr | ₹-155 Cr | ₹-297 Cr | — |
| FCF | ₹257 Cr | ₹-550 Cr | ₹357 Cr | ₹910 Cr | ₹241 Cr | -1.6% |
| Total Assets | ₹2272 Cr | ₹3667 Cr | ₹7040 Cr | ₹7033 Cr | ₹7366 Cr | +34.2% |
| Total Debt | ₹84.4 Cr | ₹877 Cr | ₹2781 Cr | ₹2478 Cr | ₹2359 Cr | +129.9% |
| Shareholders' Equity | ₹1908 Cr | ₹2196 Cr | ₹2586 Cr | ₹2854 Cr | ₹3903 Cr | +19.6% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
ERIS vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 NATCOPHARM NATCOPHARM | — | — | Pending | 15.4% | — |
 ASTRAZEN ASTRAZEN | — | — | Pending | 21.5% | 103.5× |
 WOCKPHARMA WOCKPHARMA | — | — | Pending | -1.0% | — |
 GLAND GLAND | — | — | Pending | 9.9% | 27.2× |
 EMCURE EMCURE | — | — | Pending | 18.7% | — |
Click a ticker to view its fair-value analysis.
Dividend History
5 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹20.71/sh
Last payout
2025-02-13
₹7.35
Peak payout
₹7.35
Trailing yield
—
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
Risk Analysis
Volatility & drawdown
Risk profile of ERIS →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for ERIS →
Compare
Head-to-head with peers
Compare ERIS side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse ERISNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.